Mellott CE, Jaworski R, Carrico J, Talbird SE, Dobrowolska I, Golicki D, Bencina G, Clinkscales M, Karamousouli E, Eiden AL, Sabale U. Public health impact and return on investment of the pediatric immunization program in Poland. Expert Rev Vaccines. 2023 Dec;22(11):1114-25. doi: 10.1080/14760584.2023.2275712
Falope O, Nyaku MK, O'Rourke C, Hermany LV, Plavchak B, Mauskopf J, Hartley L, Kruk ME. Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs. Expert Rev Vaccines. 2022 Nov 1;21(11):1621-36. doi: 10.1080/14760584.2022.2116007
Poulos C, Boeri M, Coulter JR, Huang L, Schley K, Pugh SJ. Travelers' preferences for tick-borne encephalitis vaccination. Expert Rev Vaccines. 2022 Oct 1;21(10):1495-504. doi: 10.1080/14760584.2022.2108798
Patterson BJ, Myers K, Stewart A, Mange B, Hillson EM, Poulos C. Preferences for herpes zoster vaccination among adults aged 50 years and older in the United States: results from a discrete choice experiment. Expert Rev Vaccines. 2021 Jul 22. doi: 10.1080/14760584.2021.1910502
MacLeod S, Tkatch R, Kraemer S, Fellows A, McGinn M, Schaeffer J, Yeh CS. The impact of COVID-19 on informal caregivers in the US. Int J Aging Res. 2021 Jan;4(87).
Huang L, Mauskopf J, Farkouh R, Masaquel C. Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, The Netherlands, and Canada. Expert Rev Vaccines. 2021 Jan;20(1):59-72. doi: 10.1080/14760584.2021.1878030
Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018 Nov;17(11):1021-35. doi: 10.1080/14760584.2018.1538801
Roberts J, Price J, Nelson LM, Burchinal M, Hennon E, Barnes B. Receptive vocabulary, expressive vocabulary, and speech production of boys with fragile X syndrome in comparison to boys with Down syndrome. Am J Ment Retard. 2007 May 1;112:177-93.
Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, Humphries SE, Talmud PJ. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92(9):969-75.